Next 10 |
home / stock / celc / celc articles
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targ...
MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targ...
MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targe...
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targe...
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targe...
Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate ...
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targe...
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targe...
Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway...
News, Short Squeeze, Breakout and More Instantly...
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targ...
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for...
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $24.00 for CELC on 2024-03-28 07:08:00. The adjusted price target was set to $24.00. At the time of the announcement, CELC was trading at $18.16. CELC currently trades -4.12% versus its 52 week high of...